[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354877-105":59,"doc-detail-354877-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","molecular-imaging-in-gastric-cancer-18ffdg-and-fibroblast-activation-protein-targeted-petct","Molecular Imaging in Gastric Cancer - [18F]FDG and Fibroblast Activation Protein-Targeted PET/CT","","Gastric cancer remains a major global health burden, and accurate staging and response assessment are essential for optimal management. 2-[18F]-Fluoro-2-deoxy-D-glucose ([18F] FDG) PET/CT is widely used, but its sensitivity varies, especially in poorly cohesive, mucinous, and signet ring carcinomas with low glucose metabolism. Fibroblast activation protein-targeted imaging visualizes tumor stroma, with radiolabeled FAPIs showing high tumor-to-background contrast and consistent uptake across subtypes. Evidence suggests FAPI PET/CT improves diagnostic accuracy and complements response evaluation, with potential theranostic use. Further prospective studies are needed to standardize protocols and clarify clinical impact.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/molecular-imaging-in-gastric-cancer-18ffdg-and-fibroblast-activation-protein-targeted-petct/354877/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/molecular-imaging-in-gastric-cancer-18ffdg-and-fibroblast-activation-protein-targeted-petct/354877.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is [18F]FDG PET/CT sensitivity variable in gastric cancer?","Question",{"text":112,"@type":113},"Sensitivity varies with tumor histology and molecular phenotype. Poorly cohesive, mucinous, and signet ring cell carcinomas often show low or absent [18F]FDG uptake due to reduced glucose transporter expression and abundant mucin, leading to false-negative results.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the rationale for fibroblast activation protein (FAP)–targeted PET/CT in gastric cancer?",{"text":117,"@type":113},"FAP-targeted tracers visualize the tumor stroma by targeting cancer-associated fibroblasts. This approach focuses on tumor microenvironment activity rather than tumor-cell glucose metabolism.",{"name":119,"@type":110,"acceptedAnswer":120},"How does FAPI PET/CT compare with FDG PET/CT for clinical evaluation?",{"text":121,"@type":113},"Comparative evidence indicates that FAPI PET/CT can enhance diagnostic accuracy, provide complementary information for assessing treatment response, and may enable theranostic applications, including in [18F]FDG-negative tumors.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354877,1790161947,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","J Gastric Cancer. 2026 Jan;26(1):62-75 [https://doi.org/10.5230/jgc.2026.26.e4](https://doi.org/10.5230/jgc.2026.26.e4)[ ](https://doi.org/10.5230/jgc.2026.26.e4)pISSN 2093-582X·eISSN 2093-5641  \nReview Article  \nReceived: Oct 14, 2025  \nRevised: Nov 17, 2025  \nAccepted: Nov 18, 2025  \nPublished online: Dec 24, 2025  \nCorrespondence to  \nMinseok Suh  \nDepartment of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea. [Email: mandu3710@gmail.com](Email: mandu3710@gmail.com)  \nCopyright © 2026. Korean Gastric Cancer Association  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://](https://)[ ](https://)[creativecommons.org/licenses/by-nc/4.0](creativecommons.org/licenses/by-nc/4.0)) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nORCID iDs  \nChaninart Sakulpisuti  [https://orcid.org/0000-0003-0879-088X](https://orcid.org/0000-0003-0879-088X)Minseok Suh  [https://orcid.org/0000-0002-6932-8552](https://orcid.org/0000-0002-6932-8552)  \nFunding  \nThis work was supported by grant of the MD-PhD/Medical Scientist Training Program through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (RS-2024-00408027) .  \nMolecular Imaging in Gastric Cancer:[18 F]FDG and Fibroblast Activation Protein-Targeted PET/CT  \nChaninart Sakulpisuti  1,2, Minseok Suh  1  \n1Department of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea  \n2Division of Nuclear Medicine, Department of Diagnostic and Therapeutic Radiology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand  \nABSTRACT  \nGastric cancer remains a major global health burden, and accurate staging and response assessment are essential for optimal management. 2-[18F]-Fluoro-2-deoxy-D-glucose ([18F] FDG) positron emission tomography (PET)/computed tomography (CT) is widely used in oncology. However, it exhibits variable sensitivity in gastric cancer, particularly in poorly cohesive, mucinous, and signet ring cell carcinomas with low glucose metabolism. These limitations have prompted interest in fibroblast activation protein-targeted imaging, which visualizes the tumor stroma rather than the tumor cells. Radiolabeled fibroblast activation protein inhibitors (FAPIs) exhibit high tumor-to-background contrast and consistent uptake across histological subtypes, offering improved lesion detectability even in [18F]FDG-negative tumors. This review outlines the evolving role of PET/CT in gastric cancer, with a focus on [18F]FDG and FAPI tracers. Comparative evidence indicates that FAPI PET/CT enhances diagnostic accuracy, provides complementary information for evaluating treatment response, and offers potential theranostic applications. Further prospective studies are needed to establish standardized protocols and define the clinical impact of FAPI PET/CT.  \nKeywords: Molecular imaging; Positron emission tomography; Fluorodeoxyglucose F18; Fibroblast activation protein alpha  \nINTRODUCTION  \nGastric cancer remains a major global health challenge, ranking fifth in terms of incidence and cancer-related mortality worldwide [1]. In Korea, it is the fourth most commonly diagnosed malignancy and the fourth leading cause of cancer-related deaths, with a persistently high disease burden despite advances in screening and treatment [2] . Accurate staging at diagnosis is essential for selecting appropriate therapy, predicting prognosis, and avoiding unnecessary surgery [3] .  \nCurrent imaging strategies for gastric cancer rely primarily on endoscopy and contrastenhanced computed tomography (CECT) for anatomical staging [4-7] . Positron emission  \n[https://jgc-online.org](https://jgc-online.org) 62  \nFDG ","cbCaigyMKTCNBCAA","https://ap.wps.com/l/cbCaigyMKTCNBCAA","pdf",12535033,14,"English","# Abstract\n# Introduction\n## Imaging strategies in gastric cancer\n## Limitations of [18F]FDG PET/CT","[{\"question\":\"Why is [18F]FDG PET/CT sensitivity variable in gastric cancer?\",\"answer\":\"Sensitivity varies with tumor histology and molecular phenotype. Poorly cohesive, mucinous, and signet ring cell carcinomas often show low or absent [18F]FDG uptake due to reduced glucose transporter expression and abundant mucin, leading to false-negative results.\"},{\"question\":\"What is the rationale for fibroblast activation protein (FAP)–targeted PET/CT in gastric cancer?\",\"answer\":\"FAP-targeted tracers visualize the tumor stroma by targeting cancer-associated fibroblasts. This approach focuses on tumor microenvironment activity rather than tumor-cell glucose metabolism.\"},{\"question\":\"How does FAPI PET/CT compare with FDG PET/CT for clinical evaluation?\",\"answer\":\"Comparative evidence indicates that FAPI PET/CT can enhance diagnostic accuracy, provide complementary information for assessing treatment response, and may enable theranostic applications, including in [18F]FDG-negative tumors.\"}]","Molecular Imaging in Gastric Cancer - [18F]FDG and Fibroblast Activation Protein-Targeted PET/CT | PDF",1790114569,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f1b86ff85bc8a526adbe9c8b2f5f34e4.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61925cebc7a096a3ea94768513e13553.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b5641844c4e1f3477b6ebe6c9f200281.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ae210cf2294f50e0b7eba10efc507031.webp",980,1306]